News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–28
Matches
28
Sources here
10
Companies here
1
Search results Stored financial headlines

Active search

28 matching headlines

Ticker or company: CRVOMain company stories
Clear
Latest

Stock Titan Deals and strategy

CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares

RA Capital Management and its affiliated funds have disclosed an 8.6% beneficial ownership stake in CervoMed Inc. (CRVO), primarily through warrants exercisable for 1,266,143 shares of common stock. This disclosure, based on a SCHEDULE 13G/A filing, indicates that RA Capital, along with Peter Kolchinsky and Rajeev Shah, collectively hold shared voting and dispositive power over these warrant shares. …

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
Stock Titan Deals and strategy Main company 🇺🇸 United States

CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing

CVI Investments, Inc. and Heights Capital Management, Inc. have filed an amended Schedule 13G/A for CervoMed Inc. (CRVO), reporting a 0% beneficial ownership in the company. This filing indicates that both entities collectively hold no shares and possess no voting or dispositive power over …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.53% in CervoMed Inc. (CRVO), totaling 1,592,863 shares of common stock. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the investment manager, granting them shared …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingView Regulatory and legal Main company 🇺🇸 United States

CRVO: Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS

CervoMed Inc. (CRVO) has reported significant clinical and regulatory progress for its Phase III-ready drug targeting Dementia with Lewy Bodies (DLB), showing strong data supporting its mechanism and efficacy. The company is also expanding its pipeline into Progressive Supranuclear Palsy (PPA) and Amyotrophic Lateral …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

CervoMed reports Q2 2026: $24.9M cash position, net loss $6.6M; advancing neflamapimod toward Phase 3

CervoMed reported its second-quarter 2026 results, highlighting a cash position of approximately $24.9 million and a net loss of $6.6 million. The company completed two equity financings in June, raising $20.5 million, extending its cash runway through Q3 2027. CervoMed is strategically focusing on …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Canaccord cuts CervoMed stock price target on funding uncertainty

Canaccord Genuity lowered its price target on CervoMed Inc. to $18 from $27, citing uncertainty regarding funding for the company's lead drug candidate, neflamapimod, despite maintaining a Buy rating. The stock has seen a significant decline, but the firm believes it remains undervalued due …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

CervoMed (NASDAQ: CRVO) details Q2 2026 loss, cash runway and DLB program

CervoMed (NASDAQ: CRVO) reported its Q2 2026 financial results, detailing a net loss of $6.6 million and highlighting that its current cash of $24.9 million is expected to fund operations through Q3 2027. The company is prioritizing a strategic partnership to advance its lead …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Manila Times Earnings Main company 🇺🇸 United States

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed Inc. announced its second-quarter 2026 financial results, highlighting significant progress in its clinical programs for age-related brain disorders. The company is actively seeking a strategic partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies (DLB) after new analyses reinforced its …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Balance sheet Main company 🇺🇸 United States

CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely

CervoMed (NASDAQ:CRVO) is highlighted as a company that needs to carefully manage its cash burn, as it currently has only about 11 months of cash runway based on its June 2026 cash balance and annual burn rate of US$28 million. The article notes that …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

CervoMed (NASDAQ: CRVO) raises $20.5M, ends Q2 with $24.9M cash

CervoMed (NASDAQ: CRVO) reported a Q2 2026 net loss of $6.6 million and a first-half net loss of $14.5 million, primarily due to R&D and administrative expenses without product revenue. The clinical-stage biotech successfully raised approximately $20.5 million through a private placement and a …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

CervoMed Inc. 2026: Revenue $0 Net income ($6.57M), EPS ($0.64) — 10-Q Summary

CervoMed Inc. reported a net loss of ($6.57M) and ($0.64) EPS for the 2026 quarter, with grant revenue of $0, a significant drop from the prior year's $1.76M. The company completed $20.5M in financing for R&D, focusing on advancing neflamapimod clinical programs, particularly for …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CervoMed Inc (CRVO) Earnings Forecast: Future EPS & Revenue Growth Estimates

CervoMed Inc (CRVO) has an earnings forecast score of 8.00, placing it 171st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $20.00, with a high of $31.00 and a low of $15.00. Based on ratings from 6 …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

CervoMed to Share Drug Program Progress at Aug. 11 Chat

CervoMed (NASDAQ: CRVO) will participate in a fireside chat and investor meetings at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, to discuss recent progress in its neflamapimod clinical development program. The fireside chat is scheduled for 11:30–11:55 AM ET and …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Market update Main company 🇺🇸 United States

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Inc. announced its participation in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. Management will discuss recent progress in the clinical development program for neflamapimod, a lead drug candidate for age-related brain …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

CervoMed Inc expected to post a loss of 87 cents a share - Earnings Preview

CervoMed Inc is expected to report an upcoming earnings loss of 87 cents per share. This information, provided by Refinitiv and featured on TradingView News, is part of an earnings preview.

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

CervoMed (NASDAQ: CRVO) receives UK ILAP Innovation Passport for DLB drug

CervoMed Inc. announced that its lead drug candidate, neflamapimod, has been granted an Innovation Passport by the UK, allowing its entry into the Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). This designation is designed to accelerate …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Guidance Main company 🇺🇸 United States

CervoMed Announces Neflamapimod Awarded Innovation Passport

CervoMed announced that its drug candidate, neflamapimod, has received an Innovation Passport under the UK's Innovative Licensing and Access Pathway (ILAP) for treating Dementia with Lewy Bodies (DLB). This designation aims to accelerate market access and facilitate patient access to new medicines in the …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CervoMed Inc (CRVO) Valuation: PE, PB & Fair Value Analysis

CervoMed Inc (CRVO) currently holds a valuation score of 6.43, placing it 301st out of 385 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is reported as -0.79, significantly below its recent high and above its recent low. Key valuation …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CRVO|CervoMed Inc|Price:2.555|Chg%:-0.005

This article provides a comprehensive stock analysis of CervoMed Inc (CRVO) by TradingKey. It highlights that CervoMed's fundamentals are healthy with significant growth potential, although its valuation is considered fairly valued within the Biotechnology & Medical Research industry. Analysts overwhelmingly rate it as a …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

CervoMed Inc (CRVO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of CervoMed Inc (CRVO), outlining major individual and institutional holdings. Key individuals like Joshua S. Boger, Sylvie L. Gregoire, and John J. Alam hold significant proportions, alongside institutional investors such as Morgan Stanley. The report also includes quarterly …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CervoMed Inc (CRVO) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for CervoMed Inc (CRVO), covering operating, investing, and financing activities. It presents financial figures for various quarters and years, allowing users to assess the company's financial soundness and stability. The article also includes …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Deals and strategy Main company 🇺🇸 United States

CervoMed Inc (CRVO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of CervoMed Inc (CRVO) stock performance, focusing on its dividend history and stock split events. It indicates that CervoMed has not distributed dividends in the past five years but lists several merger-related stock splits occurring in August 2023 and …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CRVO Income Statement - CervoMed Inc

This article presents the quarterly income statement for CervoMed Inc (CRVO), detailing financial performance metrics such as revenue, operating expenses, and net income over a long period. It includes year-over-year percentage changes and absolute values for various financial line items. Additionally, the article features …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

CervoMed Inc (CRVO) Institutional Confidence

CervoMed Inc (CRVO) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 14.61%, which is a significant decrease of 67.97% quarter-over-quarter. Key institutional shareholders include Morgan Stanley …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

CervoMed Inc. Revenue Breakdown – NASDAQ:CRVO

CervoMed Inc. (NASDAQ:CRVO) generated $4.01 million USD in revenue last year, primarily from its Clinical and Preclinical Product Candidates segment. This also represents its entire revenue from the United States, indicating a sole geographic focus for its current operations. This revenue figure marks a …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Nigeria Analyst action Main company 🇺🇸 United States

H.C. Wainwright reiterates CervoMed stock rating at buy, $25 target By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $25.00 price target for CervoMed (NASDAQ: CRVO), indicating a significant potential upside from its current stock price. Despite a recent stock decline, analyst consensus remains strong. The company recently presented new analyses on its investigational …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Analyst action Main company 🇺🇸 United States

CRVO Reiterated by HC Wainwright & Co. -- Rating Maintained at B

HC Wainwright & Co. has reiterated a Buy rating for CervoMed (CRVO) with an unchanged price target of $25.00, expressing confidence in the stock's potential. Despite a low GF Score™ of 35/100, which suggests challenges in profitability and growth, the company shows strong financial …

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Market update Main company 🇺🇸 United States

CervoMed ประกาศข้อมูลใหม่จากการทดลองทางคลินิก ข้อมูลตัวบ่งชี้ทางชีวภาพในพลาสมา และข้อมูลภาพถ่ายทางการแพทย์ ณ งานประชุม AAIC 2026 สำหรับยา Neflamapimod ในการรักษาโรคสมองเสื่อมจากภาวะ Lewy Bodies (DLB)

CervoMed announced new clinical trial data for its drug Neflamapimod at AAIC 2026. The data includes plasma biomarker information and medical imaging data. This information concerns the treatment of Dementia with Lewy Bodies (DLB) with Neflamapimod.

CRVO main company
Sharemaestro market context Price below Trend Line 52 weeks -70.1% CRVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context